Ethanol injection for the treatment of benign prostatic hyperplasia.
Recent studies examining the benefit of prostatic ethanol injection for symptomatic benign prostatic hyperplasia (BPH) have demonstrated significant postsurgical improvements (after 1 to 3 months) in BPH parameters such as symptom score, flow rate, and postvoid residual. Transperineal and transurethral injection routes have been reported to be safe and well-tolerated in men. Animal and human studies demonstrate that this treatment has a direct necrotic effect on prostatic tissue with negligible systemic absorption. Although this technique demonstrates promise as a minimally invasive treatment for BPH, further study of a large series of men is clearly required to define its benefit.
Kim
Edward D
ED
Department of Surgery, Division of Urology, University of Tennessee Medical Center, 1928 Alcoa Highway, Suite 127, Knoxville, TN 37920, USA. ekim@mc.utmck.edu
D000818:Animals; D004285:Dogs; D000431:Ethanol / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D008297:Male; D023421:Models, Animal; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery; D012997:Solvents / Q000008:administration & dosage* / Q000627:therapeutic use; D020728:Transurethral Resection of Prostate
D012997:Solvents; D000431:Ethanol